Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β production capable of improving dendritic cell function

European Journal of Immunology

Volumn 43, Issue 7, 2013, Pages 1849-1861

  Gatti, Gerardo ^a,b   Nuñez, Nicolás Gonzalo ^a   Nocera, David Andrés ^a   Dejager, Lien ^c   Libert, Claude ^c   Giraudo, Constancio ^b   Maccioni, Mariana ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b Laboratorio de Alta Complejidad Córdoba   (Argentina)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Dendritic cells; DsRNA; IFN ; TLR3; Tumor immunity

Indexed keywords

BETA INTERFERON; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; POLYADENYLIC POLYURIDYLIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; STAT1 PROTEIN;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR IMMUNITY;

DENDRITIC CELLS; DSRNA; IFN-Β; TLR3; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOMIMETICS; BLOTTING, WESTERN; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERFERON-BETA; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; POLY A-U; POLY I-C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, DOUBLE-STRANDED; TRANSFECTION;

EID: 84879996045     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242902     Document Type: Article

References (52)

1. Kawai, T. and Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010. 11: 373-384.
2. Hennessy, E. J., Parker, A. E. and O'Neill, L. A., Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 2010. 9: 293-307.
3. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S. et al., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006. 441: 101-105.
4. Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y. T. et al., Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005. 433: 887-892.
5. Tabiasco, J., Devêvre, E., Rufer, N., Salaun, B., Cerottini, J. C., Speiser, D. and Romero, P., Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J. Immunol. 2006. 177: 8708-8713.
6. Wang, L., Smith, D., Bot, S., Dellamary, L., Bloom, A. and Bot, A., Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J. Clin. Invest. 2002. 110: 1175-1184.
7. Currie, A. J., van der Most, R. G., Broomfield, S. A., Prosser, A. C., Tovey, M. G. and Robinson, B. W., Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 2008. 180: 1535-1544.
8. Salaun, B., Coste, I., Rissoan, M. C., Lebecque, S. J. and Renno, T., TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 2006. 176: 4894-4901.
9. Estornes, Y., Toscano, F., Virard, F., Jacquemin, G., Pierrot, A., Vanbervliet, B., Bonnin, M. et al., dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ. 2012. 19: 1482-1494.
10. Salaun, B., Romero, P. and Lebecque, S., Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur. J. Immunol. 2007. 37: 3311-3318.
11. Van, D. N., Roberts, C. F., Marion, J. D., Lépine, S., Harikumar, K. B., Schreiter, J., Dumur, C. I. et al., Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J. 2012. 26: 3188-3198.
12. Trinchieri, G., Type I interferon: friend or foe?. J. Exp. Med. 2010. 207: 2053-2063.
13. Wang, B. X., Rahbar, R. and Fish, E. N., Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 2011. 31: 545-552.
14. Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H. et al., Type I interferon is selectively required by dendritic cells for immunerejection of tumors. J. Exp. Med. 2011. 208: 1989-2003.
15. Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S. and Weiss, S., Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 2010. 120: 1151-1164.
16. U'Ren, L., Guth, A., Kamstock, D. and Dow, S., Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol. Immunother. 2010. 59: 587-598.
17. Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S. R., Kranz, D. M., Murphy, K. M. and Gajewski, T. F., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011. 208: 2005-2016.
18. Andreani, V., Gatti, G., Simonella, L., Rivero, V. and Maccioni, M., Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res. 2007. 67: 10519-1027.
19. Núñez, N. G., Andreani, V., Crespo, M. I., Nocera, D. A., Breser, M. L., Morón, G., Dejager, L. et al., IFN-β produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012. 72: 592-603.
20. Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D. and Romero, P., Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 2007. 13: 4565-4574.
21. Salaun, B., Zitvogel, L., Asselin-Paturel, C., Morel, Y., Chemin, K., Dubois, C., Massacrier, C. et al., TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 2011. 71: 1607-1614.
22. Idoyaga, J., Moreno, J. and Bonifaz, L., Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands. Cancer Immunol. Imunother. 2007. 56: 1237-1250.
23. Condamine, T. and Gabrilovich, D. I., Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011. 32: 19-25.
24. Regis, G., Pensa, S., Boselli, D., Novelli, F. and Poli, V., Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling. Semin. Cell Dev. Biol. 2008. 19: 351-359.
25. Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. et al., Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008. 452: 591-597.
26. Gautier, G., Humbert, M., Deauvieau, F., Scuiller, M., Hiscott, J., Bates, E. E., Trinchieri, G. et al., A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 2005. 201: 1435-1446.
27. Conforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., Ryffel, B. et al., Opposing effects of Toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 2010. 70: 490-500.
28. Kanzler, H., Barrat, F. J., Hessel, E. M. and Coffman, R. L., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007. 13: 552-559.
29. Lacour, J., Laplanche, A., Malafosse, M., Gallot, D., Julien, M., Rotman, N., Guivarc'h, M. et al., Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur. J. Surg. Oncol. 1992. 18: 599-604.
30. Jeung, H. C., Moon, Y. W., Rha, S. Y., Yoo, N. C., Roh, J. K., Noh, S. H., Min, J. S. et al., Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann. Oncol. 2008. 19: 520-526.
31. Kemeny, N., Yagoda, A., Wang, Y., Field, K., Wrobleski, H. and Whitmore, W., Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer. Cancer 1981. 48: 2154-2167.
32. Lacour, J., Lacour, F., Spira, A., Michelson, M., Petit, J. Y., Delage, G., Sarrazin, D. et al., Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet. 1980. 2:161-164.
33. Laplanche, A., Alzieu, L., Delozier, T., Berlie, J., Veyret, C., Fargeot, P., Luboinski, M. et al., Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year followup analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res. Treat. 2000. 64:189-191.
34. Nicodemus, C. F. and Berek, J. S., TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010. 2: 137-140.
35. Sadik, C. D., Bachmann, M., Pfeilschifter, J. and Mühl, H., Activation of interferon regulatory factor-3 via Toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA. Nucleic Acids Res. 2009. 37: 5041-5056.
36. Guillot, L., Le Goffic, R., Bloch, S., Escriou, N., Akira, S., Chignard, M. and Si-Tahar, M., Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J. Biol. Chem. 2005. 280: 5571-5580.
37. Paone, A., Starace, D., Galli, R., Padula, F., De Cesaris, P., Filippini, A., Ziparo, E. et al., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008. 29: 1334-1342.
38. Chin, A. I., Miyahira, A. K., Covarrubias, A., Teague, J., Guo, B., Dempsey, P. W. and Cheng, G., Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010. 70: 2595-2603.
39. Galli, R., Starace, D., Busà, R., Angelini, D. F., Paone, A., De Cesaris, P., Filippini, A. et al., TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J. Immunol. 2010. 184: 6658-6669.
40. Weber, A., Kirejczyk, Z., Besch, R., Potthoff, S., Leverkus, M. and Häcker, G., Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ. 2010. 17: 942-951.
41. Navarro, S., Colamonici, O. R. and Llombart-Bosch, A., Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod. Pathol. 1996. 9:150-156.
42. Schijns, V. E., Haagmans, B. L., Wierda, C. M., Kruithof, B., Heijnen, I. A., Alber, G. and Horzinek, M. C., Mice lacking IL-12 develop polarized Th1 cells during viral infection. J. Immunol. 1998. 160: 3958-3964.
43. Oxenius, A., Karrer, U., Zinkernagel, R. M. and Hengartner, H., IL-12 is not required for induction of type 1 cytokine responses in viral infections. J. Immunol. 1999. 162: 965-973.
44. Apetoh, L., Locher, C., Ghiringhelli, F., Kroemer, G. and Zitvogel, L., Harnessing dendritic cells in cancer. Semin. Immunol. 2011. 23: 42-49.
45. Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M. et al., Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009. 206:1589-1602.
46. Yang, M., Xiao, Z., Lv, Q., Liu, X., Zhou, L., Chen, X., Chen, M. et al., The functional expression of TLR3 in EPCs impairs cell proliferation by induction of cell apoptosis and cell cycle progress inhibition. Int. Immunopharmacol. 2011. 11: 2118-2124.
47. Zimmer, S., Steinmetz, M., Asdonk, T., Motz, I., Coch, C., Hartmann, E., Barchet, W. et al., Activation of endothelial Toll-like receptor 3 impairs endothelial function. Circ. Res. 2011. 108: 1358-1366.
48. Guo, Z., Chen, L., Zhu, Y., Zhang, Y., He, S., Qin, J., Tang, X. et al., Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells. Oncol. Rep. 2012. 27: 396-402.
49. Ma, B., Dela Cruz, C. S., Hartl, D., Kang, M. J., Takyar, S., Homer, R. J., Lee, C. G. et al., RIG-like helicase innate immunity inhibits vascular endothelial growth factor tissue responses via a type I IFN-dependent mechanism. Am. J. Respir. Crit. Care Med. 2011. 183: 1322-1335.
50. Bergé, M., Bonnin, P., Sulpice, E., Vilar, J., Allanic, D., Silvestre, J. S., Lévy, B. I. et al., Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am. J. Pathol. 2010. 177:3192-201.
51. Wu, C. Y., Yang, H. Y., Monie, A., Ma, B., Tsai, H. H., Wu, T. C. and Hung, C. F., Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol. Immunother. 2011. 60:1085-1096.
52. Livak, K. J. and Schmittgen, T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001. 25: 402-408.